Bibliography
- Kearney PM, Whelton M, Reynolds K, Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-23
- Chobanian AV, Bakris GL, Black HR, the National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42:1206-52
- Smith DHG. Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension. Drugs 2008;68:1207-25
- Unger T. The role of the rennin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 2002;89(Suppl):3A-10A
- Sica DA, Gehr TWB, Ghosh S. Clinical pharmacokinetics of losartan. Clin Pharmacokinet 2005;44:797-814
- Hernandez-Hernandez R, Sosa-Canche B, Velasco M, Angiotensin II receptor antagonists role in arterial hypertension. J Hum Hypertens 2002;16(Suppl 1):S93-9
- Lewis EJ, Hunsicker LG, Clarke WR, Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60
- Parving HH, Lehnert H, Brochner-Mortensen J, The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8
- Lane A, Engmann E, Bryson S, Single dose pharmacokinetics (PK) and pharmacodynamics (PD) of BR-A-657, an angiotensin II (AII) antagonist. Clin Pharmacol Ther 2005;77:P59-9
- Tenero DM, Martin DE, Miller AK, Effect of age and gender on the pharmacokinetics of eprosartan. Br J Clin Pharmacol 1998;46:267-70
- Hubner R, Hogemann AM, Sunzel M, Riddell JG. Pharmacokinetics of candersartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. J Hum Hypertens 1997;11:S19-25
- Sioufi A, Marfil F, Jaouen A, The effect of age on the pharmacokinetics of valsartan. Biopharm Drug Dispos 1998;19:237-44
- Herrlinger C, Klotz U. Drug metabolism and drug interactions in the elderly. Best Pract Res Clin Gastroenterol 2001;15:897-918
- Abernethy DR. Drug therapy in the elderly. In: Atkinson AJ Jr, Abernethy DR, Daniels CE, Dedrick RL, Markey SP. editors. Principles of clinical pharmacology. 2nd edition. Elsevier, Inc; San Diego: 2007. p. 375-88
- Thomas GN, Chan P, Tomlinson B. The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension. Drugs Aging 2006;23:131-55
- Hammerlein A, Derendorf H, Lowenthal DT. Pharmacokinetic and pharmacodynamic changes in the elderly. Clinical implications. Clin Pharmacokinet 1998;35:49-64
- Benet LZ, Hoener B. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 2002;71:115-21
- Davies NM, Takemoto JK, Brocks DR, Yanez JA. Multiple peaking phenomena in pharmacokinetic disposition. Clin Pharmacokinet 2010;49:351-77
- Koepsell H, Lips K, Volk C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 2007;24:1227-51
- Belmin J, Levy BI, Michel J-B. Changes in the rennin-angiotensin-aldosterone axis in later life. Drugs Aging 1994;5:391-400
- Low PA. Prevalence of orthostatic hypotension. Clin Auton Res 2008;18(Suppl 1):8-13
- Turgut F, Balogun RA, Abdel-Rahman EM. Renin-angiotensin-aldosterone system blockade effects on the kindey in the elderly: benefits and limitations. Clin J Am Soc Nephrol 2010;5:1330-9